A domain mimic increases ΔF508 CFTR trafficking and restores cAMP-stimulated anion secretion in cystic fibrosis epithelia
Open Access
- 1 July 2004
- journal article
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 287 (1) , C192-C199
- https://doi.org/10.1152/ajpcell.00337.2003
Abstract
The major disease-causing mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) is deletion of phenylalanine 508 (ΔF508), which adversely affects processing and plasma membrane targeting of CFTR. Under conditions predicted to stabilize protein folding, ΔF508 CFTR is capable of trafficking to the plasma membrane and retains cAMP-regulated anion channel activity. Overexpression is one factor that increases CFTR trafficking; therefore, we hypothesized that expression of a domain mimic of the first nucleotide-binding fold (NBF1) of CFTR, i.e., the site of F508, may be sufficient to overwhelm the quality control process or otherwise stabilize ΔF508 CFTR and thereby restore cAMP-stimulated anion secretion. In epithelial cells expressing recombinant ΔF508 human (h)CFTR, expression of wild-type NBF1 increased the amount of both core-glycosylated and mature protein to a greater extent than expression of ΔF508 NBF1. Expression of wild-type NBF1 in the ΔF508 hCFTR cells increased whole cell Cl−current density to ∼50% of that in cells expressing wild-type hCFTR. Expression of NBF1 in polarized epithelial monolayers from a ΔF508/ΔF508 cystic fibrosis mouse (MGEF) restored cAMP-stimulated transepithelial anion secretion but not in monolayers from a CFTR-null mouse (MGEN). Restoration of anion secretion was sustained in NBF1-expressing MGEF for >30 passages, whereas MGEN corrected with hCFTR progressively lost anion secretion capability. We conclude that expression of a NBF1 domain mimic may be useful for correction of the ΔF508 CFTR protein trafficking defect in cystic fibrosis epithelia.Keywords
This publication has 51 references indexed in Scilit:
- Defects in processing and trafficking of the cystic fibrosis transmembrane conductance regulatorKidney International, 2000
- Molecular pharmacology of the CFTR Cl− channelTrends in Pharmacological Sciences, 1999
- In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the MouseScience, 1999
- Comparison of the gating behaviour of human and murine cystic fibrosis transmembrane conductance regulator Cl− channels expressed in mammalian cellsThe Journal of Physiology, 1998
- The Nucleotide Binding Folds of the Cystic Fibrosis Transmembrane Conductance Regulator Are Extracellularly AccessibleBiochemistry, 1997
- Quantitative Analysis of the Packaging Capacity of Recombinant Adeno-Associated VirusHuman Gene Therapy, 1996
- A delta F508 mutation in mouse cystic fibrosis transmembrane conductance regulator results in a temperature-sensitive processing defect in vivo.Journal of Clinical Investigation, 1996
- Glycerol Reverses the Misfolding Phenotype of the Most Common Cystic Fibrosis MutationJournal of Biological Chemistry, 1996
- Cystic fibrosis: molecular biology and therapeutic implicationsScience, 1992
- High conservation of sequences involved in cystic fibrosis mutations in five mammalian speciesGenomics, 1991